Sentences with phrase «focus on biomarkers»

Many cancer researchers focus on biomarkers that could provide diagnostics for the early detection of cancer.

To this end his lab currently oversees three NIH - funded clinical trials that focus on biomarker development in cerebrovascular and lymphatic diseases.

Lauren A. M. Lebois, PhD, is a cognitive neuroscientist focusing on the biomarkers of trauma - spectrum disorders as an assistant neuroscientist in the laboratory of Kerry J. Ressler, MD, PhD.

Our LabPMM labs in the USA, Europe, and Asia offer an ever - expanding menu focused on biomarkers that have demonstrated clinical utility to support patient stratification & enrollment in clinical trials, companion diagnostic development, and optimized treatment for patients.

The research focused on the biomarkers involved in the buildup of brain plaques in the caudate and hippocampus.

This new team, focused on biomarkers, will add critical skills and fresh perspectives to the Catalyst for a Cure.

Not exact matches

Leading clinical investigations seeking to address cardiovascular risk reduction beyond lowering LDL - C focus on interrupting the atherosclerotic process (e.g., plaque formation and instability) by beneficially affecting other lipid, lipoprotein and inflammation biomarkers and cellular functions thought to be related to atherosclerosis and cardiovascular events.

Much current research in immuno - oncology focuses on improving these treatments, for example, by finding new immunotherapy targets and identifying biomarkers that predict a patient's response.

Wong's research over the past decade has focused on identifying biomarkers in saliva.

Precision cancer care focuses on identifying the specific biomarkers of a patient's cancer, which can help doctors make decisions about the best treatment options.

The team's next avenue of research will be focused on identifying a «biomarker» that can identify this distinct suppressive cell elsewhere in the body — for example, in blood or other samples — as a potential predictive clinical tool to determine when these cells are present in patients, which currently can not be done.

In 2011, he established the Immunotherapeutics Clinical Core, a specialized phase 1 outpatient unit at MSK that is focused on the conduct of novel immunotherapy trials, with a specific emphasis on pharmacodynamic biomarker identification.

As head of the Cancer Genetics Section, Uppsala University, he has longstanding experience in the development, application, validation, and standardization of new cancer biomarkers and technologies, with particular focus on hematological malignancies.

This combination of job responsibilities allows her to focus on methods to bridge the gap between research and clinical application of biomarker findings.

His research focuses predominantly on oncology molecular diagnostics, particularly the source and utility of miRNA biomarkers in blood, and the development of innovative molecular diagnostics for the identification of mutations that can guide therapeutic decision - making.

There are ongoing studies which focus on the discovery of molecular biomarkers of the VSV - ZEBOV vaccine in healthy individuals using omics - based technologies in combination with a systems biology approach,» says Ali Harandi.

Published in the Neurobiology of Aging, the study, which focused on detecting changes in the white matter connections of the brain, offers tantalizing potential for the identification of biomarkers connected to the development of dementia, including Alzheimer's disease.

Dr. Quintana's research is focused on the regulation of the adaptive and innate immune response and the identification of biomarkers for multiple sclerosis (MS) and other immune - mediated diseases.

«This work led by Professor O'Donnell is a technical tour de force, providing a wonderful resource for other biomedical researchers,» said Mike Murphy, Ph.D., programme leader, Mitochondrial Biology Unit at Cambridge University, U.K. «A particularly important aspect is the focus on platelets, which are readily available from patients» blood in diagnosis, prognosis or as a biomarker in assessing therapies.

«We focused on red - dwarf stars, which are smaller and fainter than our Sun, since we expect any biomarker signals from planets orbiting such stars to be easier to detect.»

Future studies will focus on developing biomarkers capable of making early predictions on whether patients will develop a severe form of the disease.

Woolley's research interests in microfluidics focus on using lab - on - a-chip devices to detect biomarkers related to preterm birth.

«Future research will focus on optimizing the candidate therapies discovered by our team in this study as well as developing biomarkers that can be used to test the efficacy of other potentially promising drugs,» says Dr. Rothstein

The identification of diagnostic tests or biomarkers that predict progression to active TB disease would greatly enhance TB control efforts in the United States and globally and allow physicians and public health officials to focus efforts on treatment of latent TB infection of those at greatest risk of progression to active, transmissible and potentially fatal disease.

Offering a standard biomarker test earlier in pregnancy could potentially help doctors to better identify women at risk of giving birth prematurely, thus enabling health services to focus treatments on women at highest risk, according to a new study led by King's College London.

Before he joined Moderna in 2013, Dr. Frederick was a Translational Research group leader at Aveo Oncology, focused on the generation of biomarkers for therapeutic response prediction, as well as avenues to modulate the tumor microenvironment for therapeutic benefit.

Current projects focus on air pollution, occupational exposures such as shift work, biomarkers such as melatonin, vitamin D, and sex hormones, and other factors such as physical activity, and genetic variants.

The study focuses on the discovery, confirmation and validation of novel biomarkers in a non-interventional manner applying NGS, multiplex PCR and miRNA technologies to determine the biomarkers according to free circulating DNA, RNA, miRNA of maternal plasma, serum and white blood cells along with the use of extracellular vesicles.

Data analyses can be focused on individual biomarkers, single metabolic pathways, or a comprehensive metabolic profile.

Accelerator Award is a milestone - driven award program ($ 100,000 for 1st year) focused on translational research toward therapeutics or associated biomarkers and diagnostics.

She is registred to the National Order of Biologists in the province of Palermo; collaboration in research project from 2012 to 2015 at the Department of Biopathology and Biotechnology, University of Palermo, focusing the study on the identification of molecules capable to modulate intracellular metabolic pathways for the prevention and treatment of infectious, tumor and degenerative disease, in collaboration with Prof. Angela Santoni, University of Rome; collaboration in research project in 2011 at the hospital «Villa Sofia Cervello» of Palermo to study methods can cure the genetic defect that causes thalassemia through genetic engineering; she studies different mechanisms of the differentiation and the activation of human gammadelta T cells as effector cells of the immune response against cancer and infectious diseases; she investigates about the identification and development of biomarkers of resistance and susceptibility to Mycobacterium tuberculosis infection; Valentina Orlando has published 13 papers in peer reviewed journals and 3 comunications at national and international congress.

This workshop focuses on considerations for development of a multiplexed immunoassays; examples of multiplexed assays for research release and other toxicities associated with CAR - T cells; and a novel flexible platform for biomarker screening and assessment of toxicities in samples exposed to CAR - T cells.

PHILADELPHIA --(April 18, 2018)-- An international team focused on HIV cure research spearheaded by The Wistar Institute in collaboration with the University of Pennsylvania and Vall d'Hebron Research Institute (VHIR) in Barcelona, Spain, established that the CD32 molecule is not a preferential biomarker to identify HIV silent reservoirs within the immune system of patients undergoing antiretroviral therapy (ART), as proposed by a recent landmark study.

She has been involved in the identification of early biomarkers of placental damage in cohorts of patients at high risk of pregnancy complications, with specific focus on the role of autoimmunity and of vascular inflammation.

Based on progress among the various laboratories and their collaborators, the CFC research team has narrowed their focus on three potential biomarkers.

We're focused on developing new biomarkers, but really that's for the explicit purpose of developing new therapies, new cures.

Cellecta Inc., a functional genomics solutions provider, focuses primarily on developing and implementing flexible and scalable broad - based screening and analysis approaches for drug target and biomarker discovery.

So what we now want to pursue, now that we have that resolution, is to see how we can take advantage of that to study the function of the cell at that scale so that we can use that as a biomarker because many of the clinical measurements these days focus on structure and that is usually a very late indicator of the disease.

His recent research has focused on the design and implementation of innovative algorithms to enable proteogenomic data analysis, pattern - based discovery of proteomic biomarker candidates, evaluation of data quality, assessment of variability and reproducibility in mass spectrometry based assays, and data visualization.

Trials such as the Anti-Amyloid in Asymptomatic Alzheimer's Study, or A4 Study, are now focusing on enrolling cognitively normal participants who have biomarkers suggestive of «preclinical AD,» in order to delay the onset of cognitive impairments.

To help doctors decide who should take cholesterol - lowering drugs that cost thousands of dollars a year, the focus of discussion could fall on risk models, such as the Framingham score and its successors, or other biomarkers besides various forms of cholesterol.

His work focuses on the application of computational methods to the analysis of proteomics data, ranging from proteogenomics and biomarker discovery to the targeted measurement and quantification of specific proteins.

The medical research focuses on investigating the molecular basis of complex human diseases, and seeks to find biomarkers that can help diagnose diseases and monitor their progress.

Helmsley Charitable Trust Awards Critical Path Institute a Grant to Focus on Crohn's Disease Biomarkers

My research mainly focuses on pathobiology of GI and pancreatic neuroendocrine tumors and identification of diagnostic, prognostic and therapeutic biomarkers for colorectal and pancreatic cancer.

Susan Amara, USA - «Regulation of transporter function and trafficking by amphetamines, Structure - function relationships in excitatory amino acid transporters (EAATs), Modulation of dopamine transporters (DAT) by GPCRs, Genetics and functional analyses of human trace amine receptors» Tom I. Bonner, USA (Past Core Member)- Genomics, G protein coupled receptors Michel Bouvier, Canada - Molecular Pharmacology of G protein - Coupled Receptors; Molecular mechanisms controlling the selectivity and efficacy of GPCR signalling Thomas Burris, USA - Nuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transporters

The pre-consortium will focus on identifying Crohn's disease biomarkers and laying the groundwork for future regulatory endorsement.

The Metabolomics & Proteomics Technology Unit activity focus on the identification of biomarkers and the functional characterization of metabolic pathways, applied to Research & Development of antimicrobials, vaccines, diagnostic tests or probiotics.

At Parsley Health, this a part of our comprehensive Assessment focusing on reducing your metabolic risk and testing key biomarkers without immediately resorting to medications or surgery.

Her research interests are dietary fiber, phytoestrogens from flax and soy, and whole grains, with a focus on conducting human feeding studies that measure relevant biomarkers for chronic disease prevention.